Literature DB >> 25416136

The fine line between Takayasu arteritis and giant cell arteritis.

Ari Polachek1, Rachel Pauzner, David Levartovsky, Galia Rosen, Gideon Nesher, Gabriel Breuer, Marina Anouk, Uri Arad, Hagit Sarvagyl-Maman, Ilana Kaufman, Dan Caspi, Ori Elkayam.   

Abstract

The objective of this study is to describe a series of patients above the age of 50 years with large vessel arteritis and vascular involvement typical of TAK. A retrospective review of 18 patients (median age 64 years) with emphasis on clinical characteristics, laboratory values, and vascular involvement by CT, MRI, or planar angiography. Five patients fulfilled the ACR criteria for GCA, five for TAK, three both GCA and TAK, while five patients did not fulfill the criteria for either disease. The dominant presenting symptoms were constitutional, while only a few patients had cranial or peripheral symptoms. Sixty-one percent had physical signs of vascular compromise. Temporal artery biopsy showed giant cell arteritis in six out of nine biopsies. Arterial involvement: 78 % had either involvement of the ascending aorta, the aortic arch, descending or/and abdominal aorta, 9 carotid, 12 subclavian, 5 axillary, 3 renal, 7 iliac, and 2 femoral arteries; 7 mesenteric or celiac trunk. All the patients were treated with prednisone and 50 % with steroid-sparing drug. Nine out of 15 patients (60 %) achieved remission after 1 year of follow-up. No substantial differences in the distribution of vascular involvement, type of treatment, or outcome measures were observed between patients fulfilling criteria for GCA or TAK. Vascular involvement typical of TAK in patients above the age of 50 years with large vessel arteritis seems to be more frequent than previously assumed. Our findings support the assumption that TAK and GCA represent a spectrum of the same disease.

Entities:  

Mesh:

Year:  2014        PMID: 25416136     DOI: 10.1007/s10067-014-2813-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  BSR and BHPR guidelines for the management of giant cell arteritis.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Leslie Alexander; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Pat James; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2010-04-05       Impact factor: 7.580

2.  Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification.

Authors:  M-C Park; S-W Lee; Y-B Park; N S Chung; S-K Lee
Journal:  Scand J Rheumatol       Date:  2005 Jul-Aug       Impact factor: 3.641

3.  Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan.

Authors:  Christian Agard; Jacques-H Barrier; Benoît Dupas; Thierry Ponge; Alfred Mahr; Gérard Fradet; Pascal Chevalet; Agathe Masseau; Eric Batard; Pierre Pottier; Bernard Planchon; Jean-Marie Brisseau; Mohamed-A Hamidou
Journal:  Arthritis Rheum       Date:  2008-05-15

4.  Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.

Authors:  Sergio Prieto-González; Pedro Arguis; Ana García-Martínez; Georgina Espígol-Frigolé; Itziar Tavera-Bahillo; Montserrat Butjosa; Marcelo Sánchez; José Hernández-Rodríguez; Josep M Grau; Maria C Cid
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

5.  Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients.

Authors:  Cyrielle Assie; Alain Janvresse; Didier Plissonnier; Hervé Levesque; Isabelle Marie
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

6.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

Authors:  R F Spiera; H J Mitnick; M Kupersmith; M Richmond; H Spiera; M G Peterson; S A Paget
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

7.  Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?

Authors:  Kathleen Maksimowicz-McKinnon; Tiffany M Clark; Gary S Hoffman
Journal:  Medicine (Baltimore)       Date:  2009-07       Impact factor: 1.889

8.  Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients.

Authors:  Isabelle Marie; Alice Proux; Pierre Duhaut; Etienne Primard; Laure Lahaxe; Nicolas Girszyn; Jean-Pierre Louvel; Hervé Levesque
Journal:  Medicine (Baltimore)       Date:  2009-05       Impact factor: 1.889

9.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15

10.  Takayasu arteritis.

Authors:  G S Kerr; C W Hallahan; J Giordano; R Y Leavitt; A S Fauci; M Rottem; G S Hoffman
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

View more
  6 in total

Review 1.  Imaging in Giant Cell Arteritis.

Authors:  Asad Khan; Bhaskar Dasgupta
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

2.  Successful Antiviral Treatment of Giant Cell Arteritis and Takayasu Arteritis.

Authors:  Don Gilden; Teresa M White; Lidia Nagae; William H Gurdin; Philip J Boyer; Maria A Nagel
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

3.  Serum levels of fibroblast growth factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis.

Authors:  Shoichi Fukui; Ayako Kuwahara-Takaki; Nobuyuki Ono; Shuntaro Sato; Tomohiro Koga; Shin-Ya Kawashiri; Nozomi Iwanaga; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Kiyoshi Migita; Yojiro Arinobu; Hiroaki Niiro; Yoshifumi Tada; Koichi Akashi; Takahiro Maeda; Atsushi Kawakami
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 4.  Refractory convulsive syncope in pregnancy: a rare presentation of Takayasu's arteritis - a case report and literature review.

Authors:  Gasthony Alobo; Violah Nahurira; Venice Omona; Pontius Bayo; Sam Olum
Journal:  Afr Health Sci       Date:  2021-06       Impact factor: 0.927

5.  Fewer subsequent relapses and lower levels of IL-17 in Takayasu arteritis developed after the age of 40 years.

Authors:  Shoichi Fukui; Naoki Iwamoto; Toshimasa Shimizu; Masataka Umeda; Ayako Nishino; Tomohiro Koga; Shin-Ya Kawashiri; Kunihiro Ichinose; Yasuko Hirai; Mami Tamai; Hideki Nakamura; Toshiyuki Aramaki; Nozomi Iwanaga; Yasumori Izumi; Tomoki Origuchi; Kiyoshi Migita; Yukitaka Ueki; Shuntaro Sato; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2016-12-13       Impact factor: 5.156

6.  Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.

Authors:  Kotaro Matsumoto; Katsuya Suzuki; Keiko Yoshimoto; Noriyasu Seki; Hideto Tsujimoto; Kenji Chiba; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2019-12-30       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.